~~<i id='29A38BC500'><strike id='29A38BC500'><tt id='29A38BC500'><pre id='29A38BC500'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

author：explore 2025-10-02 05:26:21 Page View：778

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Search called off for baby washed away in Pennsylvania flash flood
Next article： Alkermes shareholders re

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

New Alzheimer's drugs heat up race for early detection blood tests

MarionBerard/AFP/GettyImagesWiththeadventofdisease-modifyingAlzheimer’sdrugs,everyoneintheworldofAlz

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Will the FTC rein in IQVIA's health data empire?

AdobeThehealthdatagiantIQVIAbecameadominantforcebygobblingupitsrivals.Overdecades,itfeastedonupstart